Revelyx Bio

Revelyx is a biotechnology company dedicated to discovering and developing a new class of targeted protein degradation (TPD) medicines. The company utilizes a proprietary platform to identify small molecule degraders, such as molecular glues, that can eliminate disease-causing proteins previously considered undruggable. Primarily focused on oncology, Revelyx aims to address high unmet medical needs by harnessing the cell's natural protein disposal system. The company's approach involves the recruitment of E3 ubiquitin ligases to induce the degradation of specific pathogenic targets. Headquartered in South San Francisco, Revelyx is supported by prominent venture capital firms including The Column Group. The leadership team brings extensive experience from leading organizations such as Calico and Genentech.